文献速递心外重症与机械循环支持肺外科

中央型静脉-动脉体外膜氧合作为失代偿性右心衰竭患者肺动脉内膜剥脱术后恢复的桥接

Central venoarterial extracorporeal membrane oxygenation as a bridge to recovery after pulmonary endarterectomy in patients with decompensated right heart failure.
PubMed 文献 · J Heart Lung Transplant · 2022-03-09

在连续388例肺动脉内膜剥脱术患者中,40例(10.3%)术前因失代偿性右心衰竭入院,与其余348例择期患者比较;2014-2019年引入中央型VA-ECMO作为脱离体外循环困难的管理策略后,失代偿性右心衰竭患者院内死亡率从2005-2013年的31%降至2014-2019年的4%(p=.03)。

要点

  • 失代偿性右心衰竭患者占肺动脉内膜剥脱术患者的10.3%(40/388)。
  • VA-ECMO桥接恢复从2005-2013年的0.8%增至2014-2019年的6.3%(p=.02)。
  • 引入中央型VA-ECMO后,失代偿性右心衰竭患者院内死亡率由31%降至4%(p=.03)。

核心结论

  • 中央型VA-ECMO作为恢复桥接是一项重要治疗策略,可降低失代偿性右心衰竭患者的院内死亡率并带来良好的长期结局。

研究设计与样本

  • 对388例连续接受肺动脉内膜剥脱术的患者进行回顾性分析,其中40例(10.3%)术前因失代偿性右心衰竭入院,与其余348例择期手术患者比较。
  • 同时比较2005-2013年(n=120)与2014-2019年(n=268)两个时期,2014-2019年引入早期中央型VA-ECMO作为脱离体外循环困难的管理策略。

主要发现

  • 失代偿性右心衰竭患者比例在两个时期相似(13% vs 9%,p=.2)。
  • VA-ECMO桥接恢复的数量从2005-2013年的0.8%增至2014-2019年的6.3%(p=.02)。
  • 在2014-2019年期间,29%的失代偿性右心衰竭患者在术中从体外循环转为中央型VA-ECMO,中位持续时间为3(2-7)天。
  • 引入中央型VA-ECMO作为恢复桥接后,失代偿性右心衰竭患者的院内死亡率从2005-2013年的31%降至2014-2019年的4%(p=.03)。
  • 长期来看,失代偿性右心衰竭组与择期组出院后的功能恢复和生存相似;但5年时失代偿性右心衰竭患者更常需要肺动脉高压靶向药物治疗(45% vs 择期组20%,p=.002)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with chronic thromboembolic pulmonary hypertension (CTEPH) and decompensated right heart failure (DRHF) have worse outcomes after pulmonary endarterectomy (PEA). We reviewed the role of central veno-arterial extracorporeal membrane oxygenation (VA-ECMO) as a bridge to recovery after PEA in these patients. METHODS: Of 388 consecutive patients undergoing PEA, 40 (10.3%) were admitted with DRHF before PEA. This group was compared to the remaining 348 patients undergoing PEA (elective group). We also compared 2 periods: 2005-2013 (n = 120) and 2014-2019 (n = 268) after which early central VA-ECMO was introduced as a strategy to manage difficulty weaning from cardiopulmonary bypass (CPB). RESULTS: The proportion of patients with DRHF remained similar between the first and second period (13% vs 9%, p = .2). The number of VA-ECMO bridge to recovery increased from 0.8% in 2005-2013 to 6.3% in 2014-2019 (p = .02). In the second period, 29% of DRHF patients were transitioned intraoperatively from CPB to central VA-ECMO for a median duration of 3 (2-7) days. After the introduction of central VA-ECMO as a bridge to recovery, the hospital mortality in patients with DRHF dropped from 31% in 2005-2013 to 4% in 2014-2019 (p = .03). In the long-term, the functional recovery and survival after discharged from hospital was similar between the DRHF group and the elective group. However, at 5 years, DRHF patients more frequently required PH targeted medical therapy (45% vs 20% in the elective group, p = .002). CONCLUSIONS: Central VA-ECMO as a bridge to recovery is an important treatment strategy that can decrease hospital mortality in patients with DRHF and lead to excellent long-term outcome.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Abdelnour-Berchtold E, Donahoe L, McRae K, et al. Central venoarterial extracorporeal membrane oxygenation as a bridge to recovery after pulmonary endarterectomy in patients with decompensated right heart failure. J Heart Lung Transplant. 2022. PMID: 35370035. doi:10.1016/j.healun.2022.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。